Glenmark Generics (Europe) (GGEL) has launched the first generic of Atovaquone Proguanil in the UK following the revocation of the Malarone patent in the High court in the UK.
Atovaquone Proguanil is indicated for the prophylaxis and treatment of acute, uncomplicated p.falciparum malaria particularly where there is likely to be resistance. Based on IMS Health sales data for the 12 month period ending Sept 2012, Atovaquone Proguanil garnered sales of Euro 20.69 million in the UK.
The company has launched the drug after a judgment has been handed down in the case of Glenmark Generics (Europe) and Generics [UK] t/a Mylan v The Wellcome Foundation & Glaxo Group. The case involved the revocation of Glaxo’s patent for its anti-malarial product Malarone. Following proceedings in the High Court, Mr. Justice Arnold revoked Glaxo’s patent on the basis that it was obvious.
Glenmark Generics (Europe) is part of Glenmark Generics, which is a subsidiary of Glenmark Pharmaceuticals (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1826.10 |
Dr. Reddys Lab | 1371.60 |
Cipla | 1488.15 |
Lupin | 2251.80 |
Zydus Lifesciences | 1009.40 |
View more.. |